Zobrazeno 1 - 10
of 39
pro vyhledávání: '"A Field-Smith"'
Autor:
M Dungarwalla, A Field-Smith, C Jameson, U Riley, A Chapman, CB Bunker, CE Dearden, E Matutes
Publikováno v:
Haematologica, Vol 92, Iss 1 (2007)
Externí odkaz:
https://doaj.org/article/c6373587643b4fdf896efa28894da38c
Autor:
Robinson, Louise, Field-Smith, Antonia
Publikováno v:
In Future Healthcare Journal March 2021 8 Supplement 1:S29-S30
Autor:
guideline committee, Ruegger, Joshua, Hodgkinson, Sarah, Field-Smith, Antonia, Ahmedzai, Sam H
Publikováno v:
BMJ: British Medical Journal, 2015 Dec . 351
Externí odkaz:
https://www.jstor.org/stable/26523854
Autor:
Antonia Field-Smith, Louise Robinson
Publikováno v:
Future Healthcare Journal. 8:29-30
The COVID-19 pandemic has presented innumerable clinical and non-clinical challenges. The global healthcare community has responded with a tsunami of guidelines as the world grapples to understand this new disease. In order to communicate in this ‘
Publikováno v:
Clinical Medicine. 16:254-258
Care of people in their last days of life should be based on compassion, respect and, wherever possible, on research evidence. Previously the Liverpool Care Pathway attempted to facilitate this but it was withdrawn after an independent government rep
Publikováno v:
Addiction. Feb2013, Vol. 108 Issue 2, p385-393. 9p. 3 Charts, 2 Graphs.
Twenty-five years of volatile substance abuse mortality: a national mortality surveillance programme
Publikováno v:
Addiction. 108:385-393
Aims To investigate trends in volatile substance abuse (VSA) deaths over 25 years. Design A national mortality surveillance programme with standardised data collection procedures. Setting The UK and islands. Participants/Measurements All VSA deaths,
Autor:
Joshua, Ruegger, Sarah, Hodgkinson, Antonia, Field-Smith, Sam H, Ahmedzai, Eleanor, Samarasekera
Publikováno v:
BMJ (Clinical research ed.). 351
What you need to know In 2013, the UK Department of Health called for the abolition of the Liverpool care pathway, which was designed to bring a standard of care for the dying from the hospice sector into other settings. This move was provoked by an
Publikováno v:
Therapeutics and Clinical Risk Management. 2:271-279
The introduction of bortezomib, a novel first-in-class proteasome inhibitor, has been a major break through in the treatment of multiple myeloma. It is currently approved for the treatment of myeloma in the relapsed setting post transplant or as a se
Autor:
Antonia Field-Smith, Katherine Webber
Publikováno v:
BMJ Supportive & Palliative Care. 7:A33.1-A33
A patient’s preferred place of death (PPD) is frequently used as a marker for quality of end of life care. However, surveys of patients with life-limiting conditions indicate that “dying in preferred place” is not their highest priority (Action